Patents Assigned to Apotex, Inc.
-
Patent number: 11814356Abstract: Provided is a cabozantinib acesulfamate salt and a crystalline form thereof. Also provided are pharmaceutical compositions including the salt and crystalline form thereof, and methods of treatment of progressive, metastatic medullary thyroid cancer (MTC) or advanced renal cell carcinoma (RCC) that has been treated previously with anti-angiogenic therapy using the cabozantinib acesulfamate salt.Type: GrantFiled: March 29, 2023Date of Patent: November 14, 2023Assignee: Apotex Inc.Inventors: Fabio E. S. Souza, Alexander J. Stirk, Avedis Karadeolian, Allan W. Rey
-
Patent number: 11667656Abstract: The present invention provides novel crystalline forms of tenofovir alafenamide comprising tenofovir alafenamide and two different pharmaceutically acceptable acids, compositions and processes for the preparation thereof, and their use in the treatment of a human immunodeficiency virus (HIV) infection or a hepatitis B virus (HBV) infection.Type: GrantFiled: January 27, 2021Date of Patent: June 6, 2023Assignee: Apotex Inc.Inventors: Fabio E. S. Souza, Avedis Karadeolian, Alexander J. Stirk
-
Patent number: 11661396Abstract: The present invention provides novel crystalline forms of zuclomiphene citrate. Specific crystalline forms provided by the present invention include zuclomiphene citrate Forms APO-I, APO-II, APO-III, and APO-IV. Also provided are pharmaceutical compositions including the zuclomiphene citrate crystalline forms, processes for the preparation thereof and the use of these forms in the treatment of a disorder selected from the group including osteoporosis, bone fractures, loss of bone mineral density (BMD) and hot flashes in a subject suffering therefrom.Type: GrantFiled: January 21, 2021Date of Patent: May 30, 2023Assignee: Apotex Inc.Inventors: Fabio E. S. Souza, Mohammed Abdul Raheem, Yajun Zhao, Siva Ramarao Kakani, Minh T. N. Nguyen, Alexander J. Stirk, Allan W. Rey, Stuart P. Green
-
Patent number: 11578025Abstract: The present invention provides continuous flow processes for the preparation of the compound of Formula (2-A), an intermediate used in the preparation of zuclomiphene or a salt thereof.Type: GrantFiled: October 18, 2021Date of Patent: February 14, 2023Assignee: Apotex Inc.Inventors: Dineshkumar Patel, Avedis Karadeolian, Fabio E. S. Souza, Allan W. Rey
-
Patent number: 11440871Abstract: The present invention provides zuclomiphene salts, zuclomiphene binaphthyl hydrogen phosphate salt (1-A)·(BPA) and zuclomiphene oxalate salt (1-A)·(OXL), crystalline forms thereof and processes for the preparation thereof.Type: GrantFiled: November 11, 2020Date of Patent: September 13, 2022Assignee: Apotex Inc.Inventors: Mohammed Abdul Raheem, Siva Ramarao Kakani, Minh T. N. Nguyen, Yajun Zhao, Stuart P. Green, Fabio E. S. Souza, Alexander J. Stirk, Fatemeh Mohammadpourmir
-
Patent number: 11377456Abstract: The present invention provides a novel crystalline form of remdesivir, remdesivir Form APO-I, including remdesivir and dimethyl sulfoxide, compositions and processes for the preparation thereof, the use of this crystalline form in the treatment of a viral infection, and methods of treating viral infections using the same, and in particular, a viral infection caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2).Type: GrantFiled: May 25, 2021Date of Patent: July 5, 2022Assignee: Apotex Inc.Inventors: Fabio E. S. Souza, Alexander J. Stirk, Allan W. Rey
-
Patent number: 11345706Abstract: The present invention provides crystalline forms of Acalabrutinib, Specific crystalline forms provided by the present invention include Acalabrutinib Form APO-I, a co-crystal of Acalabrutinib and urea; APO-II, a co-crystal of Acalabrutinib and nicotinamide; APO-III, a co-crystal of Acalabrutinib and L-sorbitol; APO-IV, a crystalline form of Acalabrutinib; and APO-V, a co-crystal of Acalabrutinib and urea.Type: GrantFiled: August 23, 2018Date of Patent: May 31, 2022Assignee: Apotex Inc.Inventors: Fabio E. S. Souza, Bahareh Khalili, Annyt Bhattacharyya, Wancheng Guo, Jingda Zhang, Kun Cheng, Kangying Li
-
Patent number: 11236066Abstract: The present invention provides novel crystalline forms of niraparib tosylate. Specific crystalline forms provided by the present invention include niraparib tosylate Form APO-I, a co-crystal of niraparib tosylate and urea, and niraparib tosylate Form APO-II, a co-crystal of niraparib tosylate and oxalic acid. Also provided are pharmaceutical compositions including the niraparib tosylate crystalline forms, and the use of these forms in treatment or prevention of conditions which can be ameliorated by the inhibition of poly(ADP-ribose) polymerase (PARP), in particular certain forms of cancer.Type: GrantFiled: July 14, 2020Date of Patent: February 1, 2022Assignee: Apotex Inc.Inventors: Alexander J. Stirk, Fabio E. S. Souza, Avedis Karadeolian, Allan W. Rey
-
Patent number: 11220500Abstract: The present invention provides a novel crystalline form of Valbenazine dibesylate, Valbenazine dibesylate Form APO-I, compositions and processes for the preparation thereof, and the use of this crystalline form in the treatment of hyperkinetic disorders, including tardive dyskinesia.Type: GrantFiled: December 18, 2019Date of Patent: January 11, 2022Assignee: Apotex Inc.Inventors: Mohammed Abdul Raheem, Yajun Zhao, Minh T. N. Nguyen, Mohamed Ibrahim Zaki, Jenny L. Gerster, Stuart P. Green, Allan W. Rey
-
Patent number: 11072620Abstract: The present invention provides novel crystalline forms of Ponatinib hydrochloride. Specific crystalline forms provided by the present invention include Ponatinib hydrochloride Form APO-I, APO-III and APO-IV, each of which is obtained from acetonitrile/formic acid solutions. Additionally, Form APO-V is provided, which is obtained from concentrated hydrochloric acid.Type: GrantFiled: June 15, 2018Date of Patent: July 27, 2021Assignee: Apotex Inc.Inventors: Fabio E. S. Souza, Bahareh Khalili, Katherine A. Rantanen, Jenny L. Gerster, Annyt Bhattacharyya, Boris Gorin, Allan W. Rey
-
Patent number: 11046638Abstract: The present invention provides processes for the preparation of zuclomiphene, as well as intermediates useful in the preparation thereof. In particular, processes are provided for the carbometallation of diphenylacetylene with a compound of Formula (3) to afford either zuclomiphene or an intermediate which is converted to zuclomiphene.Type: GrantFiled: November 11, 2020Date of Patent: June 29, 2021Assignee: Apotex Inc.Inventors: Avedis Karadeolian, Fabio E. S. Souza, Michael R. Emmett, Allan W. Rey
-
Patent number: 10875846Abstract: The present invention provides processes for the preparation of Tezacaftor, as well as intermediates useful in the preparation thereof. In particular, processes are provided for the preparation of a compound of Formula (3), and its conversion to Tezacaftor (1).Type: GrantFiled: January 13, 2020Date of Patent: December 29, 2020Assignee: Apotex Inc.Inventors: Michael R. Emmett, Prabhudas Bodhuri, Yajun Zhao, Eduardo Gustavo Cammisa, Stuart P. Green
-
Patent number: 10858346Abstract: The present invention provides a novel crystalline form of Lumacaftor, specifically Lumacaftor Form APO-I, a co-crystal of Lumacaftor and nicotinamide, compositions including this crystalline form, and processes for the preparation of this crystalline form.Type: GrantFiled: October 15, 2018Date of Patent: December 8, 2020Assignee: Apotex Inc.Inventors: Fabio E. S. Souza, Bahareh Khalili, Katherine A. Rantanen
-
Patent number: 10822309Abstract: The present invention provides a novel crystalline form of Eluxadoline, Eluxadoline Form APO-I, a co-crystal of Eluxadoline and methyl nicotinate, compositions and processes for the preparation thereof, and the use of this crystalline form in the treatment of opioid-modulated disorders, and in particular, gastrointestinal disorders, including irritable bowel syndrome with diarrhea (IBS-D).Type: GrantFiled: November 14, 2019Date of Patent: November 3, 2020Assignee: Apotex Inc.Inventors: Fabio E. S. Souza, Bahareh Khalili, Annyt Bhattacharyya
-
Patent number: 10800787Abstract: The present invention provides processes for the preparation of Acalabrutinib (1), as well as intermediates useful in the preparation thereof. In particular, processes are provided for coupling of a compound of Formula (5) and 2-butynoic acid in the presence of Carbodiimide (8) to afford Acalabrutinib (1).Type: GrantFiled: April 17, 2018Date of Patent: October 13, 2020Assignee: Apotex Inc.Inventors: Prabhudas Bodhuri, Boris Gorin, Melanie R. A. Green, Gamini Weeratunga
-
Patent number: 10723739Abstract: The present invention provides processes for the preparation of Ribociclib, as well as intermediates useful in the preparation thereof. In particular, processes are provided for the preparation of a compound of Formula (4), and its conversion to Ribociclib (1).Type: GrantFiled: May 13, 2019Date of Patent: July 28, 2020Assignee: Apotex Inc.Inventors: Daoke Dou, Kangying Li, Fuchang Zhang, Jiang Pei, Wancheng Guo
-
Patent number: 10662178Abstract: The present invention provides a novel crystalline form of Olaparib comprising Olaparib and benzyl alcohol, compositions thereof, and the use of this crystalline form in the treatment of cancers, such as germline BRCA-mutated (gBRCAm) advanced ovarian cancer.Type: GrantFiled: January 30, 2019Date of Patent: May 26, 2020Assignee: Apotex Inc.Inventors: Allan W. Rey, Fabio E. S. Souza, Annyt Bhattacharyya, Bahareh Khalili
-
Patent number: 10632107Abstract: The present invention provides crystalline forms of Deutetrabenazine. Specific crystalline forms provided by the present invention include Deutetrabenazine Form APO-I, a co-crystal of Deutetrabenazine and quercetin, and Deutetrabenazine Form APO-II, a co-crystal of Deutetrabenazine and luteolin. Also provided are pharmaceutical compositions including the Deutetrabenazine crystalline forms, and the use of these forms in the treatment of tardive dyskinesia and chorea associated with Huntington's disease.Type: GrantFiled: May 13, 2019Date of Patent: April 28, 2020Assignee: Apotex Inc.Inventors: Fabio E. S. Souza, Bahareh Khalili, Allan W. Rey
-
Patent number: 10611772Abstract: The present invention provides a novel crystalline form of Ribociclib succinate, Ribociclib succinate Form APO-I, including Ribociclib succinate, benzyl alcohol and water, compositions thereof, processes for the preparation thereof, and the use of this crystalline form in the treatment of conditions associated with increased CDK4/6 kinase activity, and in particular, cancers, including certain forms of breast cancer.Type: GrantFiled: June 27, 2019Date of Patent: April 7, 2020Assignee: Apotex Inc.Inventors: Fabio E. S. Souza, Bahareh Khalili
-
Patent number: 10556887Abstract: The present invention provides processes for the preparation of Veliparib (1), as well as intermediates useful in the preparation thereof. In particular, processes are provided for the production of the compound of Formula (3), or a salt thereof, and cyclization to afford Veliparib (1).Type: GrantFiled: October 23, 2018Date of Patent: February 11, 2020Assignee: Apotex Inc.Inventors: Prabhudas Bodhuri, Kaarina K. Milnes, Melanie R. A. Green, Gamini Weeratunga, Boris Gorin